Evidence map›Paper›PMID 42883945›Full record

ArticleInternational journal of molecular sciences2026

Effect of

Aina Bellver-Sanchis, Christian Griñán-Ferré, Sylvain Sutour, Andrey S Marchev

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aina Bellver-SanchisDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, University of Barcelona, Av. Joan XXIII, 27-31, 08035 Barcelona, Spain.ORCID 0000-0001-9890-753X
Christian Griñán-FerréDepartment of Pharmacology, Toxicology and Therapeutic Chemistry, University of Barcelona, Av. Joan XXIII, 27-31, 08035 Barcelona, Spain.ORCID 0000-0002-5424-9130
Sylvain SutourNeuchâtel Platform of Analytical Chemistry, University of Neuchâtel, Avenue de Bellevaux 51, 2000 Neuchâtel, Switzerland.ORCID 0000-0001-9676-7123
Andrey S MarchevLaboratory of Eukaryotic Cell Biology, Department of Biotechnology, The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 139 Ruski Blvd., 4000 Plovdiv, Bulgaria.ORCID 0000-0002-7660-683X

Funding

Bulgarian National Science Fund KП-06-КОСТ/14
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, oxidative stress, and amyloid-beta accumulation. Natural products with antioxidant and stress-response-modulating properties are increasingly being investigated as candidate neuroprotective agents. In this study, we evaluated the effects of

Indexed as

Alzheimer DiseaseCaenorhabditis elegansNeuroprotective AgentsPlant ExtractsRhodiolaAmyloid beta-PeptidesAnimalsAntioxidantsCaenorhabditis elegans ProteinsDisaccharidesDisease Models, AnimalGlucosidesLocomotionOxidative StressPhenolsReactive Oxygen SpeciesAmyloid beta-PeptidesAntioxidantsCaenorhabditis elegans ProteinsDisaccharidesGlucosidesNeuroprotective AgentsPhenolsPlant ExtractsReactive Oxygen SpeciesrhodiolosiderosavinAlzheimer’s diseaseamyloid-betaCaenorhabditis eleganshormesisoxidative stressRhodiola rosearosavinsalidrosideSKN-1/Nrf2

Identifiers

PMID42883945
PMCPMC13665325

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.